Recent and New Strategies for Extensively-Drug Resistant Tuberculosis

Şenol, Güneş

doi:10.4274/mjima.2018.22

Cited by 2 publications

(2 citation statements)

References 75 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, there are still issues in anti-TB therapy that are yet to be addressed, though they should be in order to achieve TB control [ 5 , 6 , 7 ]. Most anti-TB drugs have limited efficiency against the latent bacilli, and therefore current therapeutic regimens require long durations to eliminate all forms of bacilli, usually leading to high adverse effects [ 8 , 9 , 10 ], poor compliance, and the emergence of drug resistance which consequently hampers TB control. Thus, there is an urgent unmet need for the development of anti-TB drugs that target latent bacilli and resistant strains [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Target Identification in Anti-Tuberculosis Drug Discovery

Capela

Félix

Clariano

et al. 2023

IJMS

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a disease that, although preventable and curable, remains a global epidemic due to the emergence of resistance and a latent form responsible for a long period of treatment. Drug discovery in TB is a challenging task due to the heterogeneity of the disease, the emergence of resistance, and uncomplete knowledge of the pathophysiology of the disease. The limited permeability of the cell wall and the presence of multiple efflux pumps remain a major barrier to achieve effective intracellular drug accumulation. While the complete genome sequence of Mtb has been determined and several potential protein targets have been validated, the lack of adequate models for in vitro and in vivo studies is a limiting factor in TB drug discovery programs. In current therapeutic regimens, less than 0.5% of bacterial proteins are targeted during the biosynthesis of the cell wall and the energetic metabolism of two of the most important processes exploited for TB chemotherapeutics. This review provides an overview on the current challenges in TB drug discovery and emerging Mtb druggable proteins, and explains how chemical probes for protein profiling enabled the identification of new targets and biomarkers, paving the way to disruptive therapeutic regimens and diagnostic tools.

show abstract

Section: Introductionmentioning

confidence: 99%

Target Identification in Anti-Tuberculosis Drug Discovery

Capela

Félix

Clariano

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there are still issues in anti-TB therapy that are yet to be fulfilled, which must be urgently addressed in order to achieve TB control [5][6][7]. Most anti-TB drugs have limited efficiency against the latent bacilli, and therefore current therapeutic regimens require long durations to eliminate all forms of bacilli, usually leading to high adverse effects [8][9][10], poor compliance, and Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.…”

Section: Introductionmentioning

confidence: 99%

Target Identification in Anti-tuberculosis Drug Discovery

Capela¹,

Félix²,

Clariano³

et al. 2023

Preprint

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) is the etiological agent of tuberculosis (TB), a disease that alt-hough preventable and curable, remains a global epidemic due to the emergence of resistance and a latent form responsible for a long period of treatment. Drug discovery in TB is a challenging task due to the heterogeneity of the disease, the emergence of resistance and an uncomplete knowledge of the pathophysiology of the disease. The limited permeability of the cell wall and the presence of multiple efflux pumps remain a major barrier to achieve effective intracellular drug accumulation. While the complete genome sequence of Mtb has been determined and several potential protein targets have been validated, the lack of adequate models for in vitro and in vivo studies is a limit-ing factor in TB drug discovery programs. In current therapeutic regimens, less than 0.5% of bac-terial proteins are targeted being the biosynthesis of the cell wall and the energetic metabolism two of the most important processes exploited for TB chemotherapeutics. This review provides an overview on the current challenges in TB drug discovery and emerging Mtb druggable proteins, and how chemical probes for protein profiling enabled the identification of new targets and bi-omarkers, paving the way to disruptive therapeutic regimens and diagnostic tools.

show abstract

Recent and New Strategies for Extensively-Drug Resistant Tuberculosis

Cited by 2 publications

References 75 publications

Target Identification in Anti-Tuberculosis Drug Discovery

Target Identification in Anti-Tuberculosis Drug Discovery

Target Identification in Anti-tuberculosis Drug Discovery

Contact Info

Product

Resources

About